Positive top line data released for study of C21 in COVID-19 patients
In hospitalised COVID-19 patients, researchers found that C21 reduced the risk of needing oxygen at the end of treatment by 40 percent.
List view / Grid view
In hospitalised COVID-19 patients, researchers found that C21 reduced the risk of needing oxygen at the end of treatment by 40 percent.
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
The chimeric hemagglutinin (HA)-based vaccine induced a strong, functional immune response that lasted at least 18 months.
Pfizer spokesperson reveals supply chain challenges and late clinical trial results contributed to its COVID-19 vaccine production target for 2020 being halved.
A 90-year old woman is the first person to receive BNT162b2, the Pfizer and BioNTech COVID-19 vaccine, outside of clinical trials.
When adjuvanted with GSK’s pandemic adjuvant system, the S-Trimer vaccine candidates induced the production of neutralising antibodies in all trial participants.
The report found that the 10 major economies could see a return of more than $466 billion by 2025, 12 times the total estimated cost of supporting the WHO’s Access to COVID-19 Tools (ACT) Accelerator.
New research suggests that adding extra COVID-19 peptides to a dose of vaccine could increase effectiveness in populations that may not respond robustly to COVID-19 vaccines.
The WHO’s World malaria report suggests the progress in eradicating malaria has slowed due to funding shortages and that COVID-19 disruptions could result in additional deaths.
The company has submitted for Emergency Use Authorization in the US and Conditional Marketing Authorization in Europe for its mRNA-1273 vaccine against COVID-19.
Dr Ash Ramzan, founder and principal consultant at Woodley BioReg, discusses how the COVID-19 pandemic has forced regulatory processes to adapt, focusing on the regulatory flexibilities introduced by the UK’s MHRA.
The designation should expedite the development and review of AB201, a recombinant protein therapy being tested in hospitalised COVID-19 patients.
If the Conditional Marketing Authorization application is approved, the COVID-19 vaccine BNT162b2 could be used in the EU by the end of 2020.
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
The WHO Regional Director for Africa urges governments to “ramp up readiness” as report suggests the region is not prepared for a COVID-19 vaccine roll-out.